This is biologically plausible; HNF1B is frequently reduced (and sometimes promoter-methylated) in colorectal carcinomas and low levels associate with recurrence and shorter disease-free survival, indicating a tumor-suppressive role [48]. This evidence concerns the gene HNF1B and neoplasm.